1.Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, DoubleBlind, Active Control, Noninferiority, Multicenter, Phase 3 Study
Gwang Ha KIM ; Hang Lak LEE ; Moon Kyung JOO ; Hong Jun PARK ; Sung Woo JUNG ; Ok-Jae LEE ; Hyungkil KIM ; Hoon Jai CHUN ; Soo Teik LEE ; Ji Won KIM ; Han Ho JEON ; Il-Kwun CHUNG ; Hyun-Soo KIM ; Dong Ho LEE ; Kyoung-Oh KIM ; Yun Jeong LIM ; Seun-Ja PARK ; Soo-Jeong CHO ; Byung-Wook KIM ; Kwang Hyun KO ; Seong Woo JEON ; Jae Gyu KIM ; In-Kyung SUNG ; Tae Nyeun KIM ; Jae Kyu SUNG ; Jong-Jae PARK
Gut and Liver 2021;15(6):841-850
Background/Aims:
The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of Mucosta Ⓡ (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis.
Methods:
This double-blind, active control, noninferiority, multicenter, phase 3 clinical trial randomly assigned 475 patients with endoscopically proven erosive gastritis to two groups: AD-203 twice daily or Mucosta Ⓡ thrice daily for 2 weeks. The intention-to-treat (ITT) analysis included 454 patients (AD-203, n=229; Mucosta Ⓡ , n=225), and the per-protocol (PP) analysis included 439 patients (AD-203, n=224; Mucosta Ⓡ , n=215). The posttreatment assessments included the primary (erosion improvement rate) and secondary endpoints (erosion and edema cure rates; improvement rates of redness, hemorrhage, and gastrointestinal symptoms). Drug-related adverse events were evaluated.
Results:
According to the ITT analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta Ⓡ -treated patients were 39.7% and 43.8%, respectively. According to the PP analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta Ⓡ -treated patients were 39.3% and 43.7%, respectively. The one-sided 97.5% lower limit for the improvement rate difference between the study groups was −4.01% (95% confidence interval [CI], –13.09% to 5.06%) in the ITT analysis and −4.44% (95% CI, –13.65% to 4.78%) in the PP analysis. The groups did not significantly differ in the secondary endpoints in either analysis. Twenty-four AD-203-treated and 20 Mucosta Ⓡ -treated patients reported adverse events but no serious adverse drug reactions; both groups presented similar adverse event rates.
Conclusions
The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (Mucosta Ⓡ ) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis.
2.The Current Status of Percutaneous Coronary Intervention in Korea: Based on Year 2014 & 2016 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry
Dong Ho SHIN ; Hyun Jae KANG ; Jae Sik JANG ; Keon Woong MOON ; Young Bin SONG ; Duk Woo PARK ; Jang Whan BAE ; Juhan KIM ; Seung Ho HUR ; Byung Ok KIM ; Dong Woon JEON ; Donghoon CHOI ; Kyoo Rok HAN
Korean Circulation Journal 2019;49(12):1136-1151
BACKGROUND AND OBJECTIVES:
In this second report from Korean percutaneous coronary intervention (K-PCI) registry, we sought to describe the updated information of PCI practices and Korean practice pattern of PCI (KP3).
METHODS:
In addition to K-PCI registry of 2014, new cohort of 2016 from 92 participating centers was appended. Demographic and procedural information, as well as in-hospital outcomes, of PCI was collected using a web-based reporting system. KP3 class C was defined as any strategy with less evidence from randomized trials and more aggressive for PCI than medical therapy or bypass-surgery.
RESULTS:
In 2016, total 48,823 PCI procedures were performed at 92 participating centers. Mean age of the patients was 65.7±11.6 years, and 71.7% were males. Overall patient characteristics and PCI practices in 2016 were similar to those in 2014. The biggest change was the decrease in the in-hospital occurrence of myocardial infarction (MI;1.6%→0.7%, p<0.001). Many associations between PCI volumes and demographic/procedural characteristics observed in 2014 have disappeared. The median of door-to-balloon time was 62 minutes, and 83.3% of ST-elevation MI patients received primary PCI within 90 minutes, while the median of total ischemic time was 168 minutes and patients who had total ischemic time within 120 and 180 minutes were 29.1% and 54.1%, respectively. The proportion of KP3 class C cases in non-acute coronary syndrome patients decreased from 13.5% in 2014 to 12.1% in 2016 (p<0.001).
CONCLUSIONS
In this second report from K-PCI registry, we described the current practices of PCI and changes from 2014 to 2016 in Korea.
3.The Current Status of Percutaneous Coronary Intervention in Korea: Based on Year 2014 & 2016 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry
Dong Ho SHIN ; Hyun Jae KANG ; Jae Sik JANG ; Keon Woong MOON ; Young Bin SONG ; Duk Woo PARK ; Jang Whan BAE ; Juhan KIM ; Seung Ho HUR ; Byung Ok KIM ; Dong Woon JEON ; Donghoon CHOI ; Kyoo Rok HAN
Korean Circulation Journal 2019;49(12):1136-1151
BACKGROUND AND OBJECTIVES: In this second report from Korean percutaneous coronary intervention (K-PCI) registry, we sought to describe the updated information of PCI practices and Korean practice pattern of PCI (KP3). METHODS: In addition to K-PCI registry of 2014, new cohort of 2016 from 92 participating centers was appended. Demographic and procedural information, as well as in-hospital outcomes, of PCI was collected using a web-based reporting system. KP3 class C was defined as any strategy with less evidence from randomized trials and more aggressive for PCI than medical therapy or bypass-surgery. RESULTS: In 2016, total 48,823 PCI procedures were performed at 92 participating centers. Mean age of the patients was 65.7±11.6 years, and 71.7% were males. Overall patient characteristics and PCI practices in 2016 were similar to those in 2014. The biggest change was the decrease in the in-hospital occurrence of myocardial infarction (MI;1.6%→0.7%, p<0.001). Many associations between PCI volumes and demographic/procedural characteristics observed in 2014 have disappeared. The median of door-to-balloon time was 62 minutes, and 83.3% of ST-elevation MI patients received primary PCI within 90 minutes, while the median of total ischemic time was 168 minutes and patients who had total ischemic time within 120 and 180 minutes were 29.1% and 54.1%, respectively. The proportion of KP3 class C cases in non-acute coronary syndrome patients decreased from 13.5% in 2014 to 12.1% in 2016 (p<0.001). CONCLUSIONS: In this second report from K-PCI registry, we described the current practices of PCI and changes from 2014 to 2016 in Korea.
Cohort Studies
;
Coronary Artery Disease
;
Humans
;
Korea
;
Male
;
Myocardial Infarction
;
Percutaneous Coronary Intervention
4.Clinical Presentation with High Penetrance in a Korean Family with Pulmonary Arterial Hypertension Associated with a BMPR2 Intron 3 Splice Site Pathogenic Variant.
Mi Jeong KIM ; Seungok LEE ; Dong Wook JEKARL ; Hyojin CHAE ; Myungshin KIM ; Hae Ok JUNG ; Doo Soo JEON
Laboratory Medicine Online 2018;8(3):119-124
Pathogenic variants of bone morphogenic protein receptor type 2 gene (BMPR2) are related to the majority of cases of heritable pulmonary arterial hypertension (PAH). Over 400 pathogenic variants have been identified. However, clinical characterization of PAH is still incomplete. We present a case of heritable PAH in a Korean family showing serious clinical presentation with high penetrance. Genetic sequencing revealed a known heterozygous BMPR2 pathogenic variant, c.418+5G>A, at a splice site of intron 3. Serious clinical presentation with high penetrance suggested that the interplay of other factors with pathologic variants might be in genotype-phenotype correlation. Further studies are needed to clarify these issues for the development of personalized medicine approaches for PAH.
Familial Primary Pulmonary Hypertension
;
Genetic Association Studies
;
Humans
;
Hypertension*
;
Hypertension, Pulmonary
;
Introns*
;
Penetrance*
;
Precision Medicine
;
Pulmonary Artery
5.Erratum: The Practice Pattern of Percutaneous Coronary Intervention in Korea: Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry.
Hyeon Cheol GWON ; Dong Woon JEON ; Hyun Jae KANG ; Jae Sik JANG ; Duk Woo PARK ; Dong Ho SHIN ; Keon Woong MOON ; Jung Sun KIM ; Juhan KIM ; Jang Whan BAE ; Seung Ho HUR ; Byung Ok KIM ; Donghoon CHOI ; Kyoo Rok HAN ; Hyo Soo KIM
Korean Circulation Journal 2017;47(4):541-541
In the article, “The Practice Pattern of Percutaneous Coronary Intervention in Korea.Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry.” in Volume 47(3), page 320-327, indexed color of Class A and Class C has been changed.
6.Diagnostic Yield and Clinical Impact of Video Capsule Endoscopy in Patients with Chronic Diarrhea: A Korean Multicenter CAPENTRY Study.
Hyun Joo SONG ; Jeong Seop MOON ; Seong Ran JEON ; Jin Oh KIM ; Jinsu KIM ; Dae Young CHEUNG ; Myung Gyu CHOI ; Yun Jeong LIM ; Ki Nam SHIM ; Byong Duk YE ; Jae Hee CHEON ; Cheol Hee PARK ; Hyun Soo KIM ; Ji Hyun KIM ; Dong Kyung CHANG ; Jae Hyuk DO ; Kyeong Ok KIM ; Byung Ik JANG ; Sung Jae SHIN
Gut and Liver 2017;11(2):253-260
BACKGROUND/AIMS: In some cases, chronic diarrhea is unexplained, and small bowel disorders may be one of the causes. The aim of this study was to assess the diagnostic yield and clinical impact of video capsule endoscopy (VCE) in patients with chronic diarrhea. METHODS: We retrospectively analyzed records from October 2002 to August 2013 in the VCE nationwide database registry (n=2,964). Ninety-one patients from 15 medical centers (60 males and 31 females; mean age, 47±19 years) were evaluated for VCE as a result of chronic diarrhea. RESULTS: The duration of chronic diarrhea was 8.3±14.7 months. The positive diagnostic yield of VCE was 42.9% (39/91). However, 15.4% (14/91) exhibited an inconsistent result, and 41.8% (38/91) were negative. Abnormal findings consistent with chronic diarrhea included erosions/aphthous ulcers (19.8%), ulcers (17.6%), mucosal erythema (3.3%), edema (1.1%), and luminal narrowing (1.1%). The most common diagnoses were functional diarrhea associated with irritable bowel syndrome in 37 patients (40.7%) and Crohn’s disease in 18 patients (19.8%). After VCE examination, the diagnosis was changed in 34.1% of the patients (31/91). Hematochezia (odds ratio [OR], 8.802; 95% confidence interval [CI], 2.126 to 36.441) and hypoalbuminemia (OR, 4.811; 95% CI, 1.241 to 18.655) are predictive factors of a positive diagnostic yield. CONCLUSIONS: VCE had a favorable diagnostic yield and clinical impact on the management of patients with chronic diarrhea.
Capsule Endoscopy*
;
Diagnosis
;
Diarrhea*
;
Edema
;
Erythema
;
Female
;
Gastrointestinal Hemorrhage
;
Humans
;
Hypoalbuminemia
;
Irritable Bowel Syndrome
;
Male
;
Phenobarbital
;
Retrospective Studies
;
Ulcer
7.The Current Status of Percutaneous Coronary Intervention in Korea: Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry.
Jae Sik JANG ; Kyoo Rok HAN ; Keon Woong MOON ; Dong Woon JEON ; Dong Ho SHIN ; Jung Sun KIM ; Duk Woo PARK ; Hyun Jae KANG ; Juhan KIM ; Jang Whan BAE ; Seung Ho HUR ; Byung Ok KIM ; Donghoon CHOI ; Hyeon Cheol GWON ; Hyo Soo KIM
Korean Circulation Journal 2017;47(3):328-340
BACKGROUND AND OBJECTIVES: Although several multicenter registries have evaluated percutaneous coronary intervention (PCI) procedures in Korea, those databases have been limited by non-standardized data collection and lack of uniform reporting methods. We aimed to collect and report data from a standardized database to analyze PCI procedures throughout the country. MATERIALS AND METHODS: Both clinical and procedural data, as well as clinical outcomes data during hospital stay, were collected based on case report forms that used a standard set of 54 data elements. This report is based on 2014 Korean PCI registry cohort data. RESULTS: A total of 92 hospitals offered data on 44967 PCI procedures. The median age was 66.0 interquartile range 57.0-74.0 years, and 70.3% were men. Thirty-eight percent of patients presented with acute myocardial infarction and one-third of all PCI procedures were performed in an urgent or emergency setting. Non-invasive stress tests were performed in 13.9% of cases, while coronary computed tomography angiography was used in 13.7% of cases prior to PCI. Radial artery access was used in 56.1% of all PCI procedures. Devices that used PCI included drug-eluting stent, plain old balloon angioplasty, drug-eluting balloon, and bare-metal stent (around 91%, 19%, 6%, and 1% of all procedures, respectively). The incidences of in-hospital death, non-fatal myocardial infarction, and stroke were 2.3%, 1.6%, and 0.2%, respectively. CONCLUSION: These data may provide an overview of the current PCI practices and in-hospital outcomes in Korea and could be used as a foundation for developing treatment guidelines and nationwide clinical research.
Angiography
;
Angioplasty, Balloon
;
Cohort Studies*
;
Data Collection
;
Drug-Eluting Stents
;
Emergencies
;
Exercise Test
;
Humans
;
Incidence
;
Korea*
;
Length of Stay
;
Male
;
Myocardial Infarction
;
Percutaneous Coronary Intervention*
;
Radial Artery
;
Registries
;
Stents
;
Stroke
8.The Practice Pattern of Percutaneous Coronary Intervention in Korea: Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry.
Hyeon Cheol GWON ; Dong Woon JEON ; Hyun Jae KANG ; Jae Sik JANG ; Duk Woo PARK ; Dong Ho SHIN ; Keon Woong MOON ; Jung Sun KIM ; Juhan KIM ; Jang Whan BAE ; Seung Ho HUR ; Byung Ok KIM ; Donghoon CHOI ; Kyoo Rok HAN ; Hyo Soo KIM
Korean Circulation Journal 2017;47(3):320-327
BACKGROUND AND OBJECTIVES: Appropriate use criteria (AUC) was developed to improve the quality of percutaneous coronary intervention (PCI). However, these criteria should consider the current practice pattern in the country where they are being applied. MATERIALS AND METHODS: The algorithm for the Korean PCI practice pattern (KP3) was developed by modifying the United States-derived AUC in expert consensus meetings. KP3 class A was defined as any strategy with evidence from randomized trials that was more conservative for PCI than medical therapy or coronary artery bypass graft (CABG). Class C was defined as any strategy with less evidence from randomized trials and more aggressive for PCI than medical therapy or CABG. Class B was defined as a strategy that was partly class A and partly class C. We applied the KP3 classification system to the Korean PCI registry. RESULTS: The KP3 class A was noted in 67.7% of patients, class B in 28.8%, and class C in 3.5%. The median proportion of class C cases per center was 2.0%. The distribution of KP3 classes varied significantly depending on clinical and angiographic characteristics. The proportion of KP3 class C cases per center was not significantly dependent on PCI volume, but rather on the percentage of ACS cases in each center. CONCLUSION: We report the current PCI practice pattern by applying the new KP3 classification in a nationwide PCI registry. The results should be interpreted carefully with due regard for the complex relationships between the determining variables and the healthcare system in Korea.
Area Under Curve
;
Classification
;
Cohort Studies*
;
Consensus
;
Coronary Artery Bypass
;
Delivery of Health Care
;
Humans
;
Korea*
;
Percutaneous Coronary Intervention*
;
Transplants
9.Quality Indicators for Small Bowel Capsule Endoscopy.
Ki Nam SHIM ; Seong Ran JEON ; Hyun Joo JANG ; Jinsu KIM ; Yun Jeong LIM ; Kyeong Ok KIM ; Hyun Joo SONG ; Hyun Seok LEE ; Jae Jun PARK ; Ji Hyun KIM ; Jaeyoung CHUN ; Soo Jung PARK ; Dong Hoon YANG ; Yang Won MIN ; Bora KEUM ; Bo In LEE
Clinical Endoscopy 2017;50(2):148-160
Capsule endoscopy (CE) enables evaluation of the entire mucosal surface of the small bowel (SB), which is one of the most important steps for evaluating obscure gastrointestinal bleeding. Although the diagnostic yield of SB CE depends on many clinical factors, there are no reports on quality indicators. Thus, the Korean Gut Image Study Group (KGISG) publishes an article titled, “Quality Indicators for Small Bowel Capsule Endoscopy” under approval from the Korean Society of Gastrointestinal Endoscopy (KSGE). Herein, we initially identified process quality indicators, while the structural and outcome indicators are reserved until sufficient clinical data are accumulated. We believe that outcomes of SB CE can be improved by trying to meet our proposed quality indicators.
Capsule Endoscopy*
;
Endoscopy, Gastrointestinal
;
Hemorrhage
10.Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis.
Choon OK KIM ; Sangil JEON ; Seunghoon HAN ; Taegon HONG ; Min Soo PARK ; Young Ran YOON ; Dong Seok YIM
Translational and Clinical Pharmacology 2017;25(1):43-51
Fimasartan is a nonpeptide angiotensin II receptor blocker. In a previous study that compared the pharmacokinetics (PK) of fimasartan between patients with hepatic impairment (cirrhosis) and healthy subjects, the exposure to fimasartan was found to be higher in patients, but the decrease of blood pressure (BP) was not clinically significant in those with moderate hepatic impairment. The aims of this study were to develop a population PK-pharmacodynamic (PD) model of fimasartan and to evaluate the effect of hepatic function on BP reduction by fimasartan using previously published data. A 2-compartment linear model with mixed zero-order absorption followed by first-order absorption with a lag time adequately described fimasartan PK, and the effect of fimasartan on BP changes was well explained by the inhibitory sigmoid function in the turnover PK-PD model overlaid with a model of circadian rhythm (NONMEM version 7.2). According to our PD model, the lower BP responses in hepatic impairment were the result of the increased fimasartan EC₅₀ in patients, rather than from a saturation of effect. This is congruent with the reported pathophysiological change of increased plasma ACE and renin activity in hepatic cirrhosis.
Absorption
;
Blood Pressure
;
Circadian Rhythm
;
Colon, Sigmoid
;
Healthy Volunteers
;
Humans
;
Linear Models
;
Liver Cirrhosis*
;
Liver*
;
Pharmacokinetics
;
Plasma
;
Receptors, Angiotensin
;
Renin

Result Analysis
Print
Save
E-mail